{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:09:58Z","timestamp":1793639398283,"version":"4.5.1"},"reference-count":261,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"unspecified","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Alliance of Associations for Rheumatology"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,2,13]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Type I interferons (IFN-I) contribute to a broad range of rheumatic and musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of IFN-I pathway activation may have clinical value. Although several IFN-I pathway assays have been proposed, the exact clinical applications are unclear. We summarise the evidence on the potential clinical utility of assays measuring IFN-I pathway activation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature review was conducted across three databases to evaluate the use of IFN-I assays in diagnosis and monitor disease activity, prognosis, response to treatment and responsiveness to change in several RMDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 366 screened, 276 studies were selected that reported the use of assays reflecting IFN-I pathway activation for disease diagnosis (n=188), assessment of disease activity (n=122), prognosis (n=20), response to treatment (n=23) and assay responsiveness (n=59). Immunoassays, quantitative PCR (qPCR) and microarrays were reported most frequently, while systemic lupus erythematosus (SLE), rheumatoid arthritis, myositis, systemic sclerosis and primary Sj\u00f6gren\u2019s syndrome were the most studied RMDs. The literature demonstrated significant heterogeneity in techniques, analytical conditions, risk of bias and application in diseases. Inadequate study designs and technical heterogeneity were the main limitations. IFN-I pathway activation was associated with disease activity and flare occurrence in SLE, but their incremental value was uncertain. IFN-I pathway activation may predict response to IFN-I targeting therapies and may predict response to different treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Evidence indicates potential clinical value of assays measuring IFN-I pathway activation in several RMDs, but assay harmonisation and clinical validation are urged. This review informs the EULAR points to consider for the measurement and reporting of IFN-I pathway assays.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002864","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T08:40:18Z","timestamp":1678178418000},"page":"e002864","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":43,"title":["Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0011-5102","authenticated-orcid":false,"given":"Javier","family":"Rodr\u00edguez-Carrio","sequence":"first","affiliation":[{"name":"Area of Immunology, University of Oviedo, Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Asturias, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Burska","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3478-5665","authenticated-orcid":false,"given":"P G","family":"Conaghan","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem A","family":"Dik","sequence":"additional","affiliation":[{"name":"Laboratory Medical Immunology, department of Immunology, Erasmus MC University Medical Center Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-7832","authenticated-orcid":false,"given":"Robert","family":"Biesen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Charit\u00e9 University Medicine Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija-Leena","family":"Eloranta","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Cavalli","sequence":"additional","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Visser","sequence":"additional","affiliation":[{"name":"EULAR, PARE Patient Research Partners, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-4671","authenticated-orcid":false,"given":"Dimitrios T","family":"Boumpas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Crete, Medical School, Heraklion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bertsias","sequence":"additional","affiliation":[{"name":"Department of Rheumatology-Clinical Immunology, University of Crete, Medical School, Heraklion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0915-7245","authenticated-orcid":false,"given":"Marie","family":"Wahren-Herlenius","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Division of Rheumatology, Stockholm, Sweden"},{"name":"Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rehwinkel","sequence":"additional","affiliation":[{"name":"Medical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Fr\u00e9mond","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris Cit\u00e9, H\u00f4pital Necker-Enfants Malades, Immuno-H\u00e9matologie et Rhumatologie p\u00e9diatriques, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K","family":"Crow","sequence":"additional","affiliation":[{"name":"Hospital for Special Surgery, Weill Cornell Medical College, Mary Kirkland Center for Lupus Research, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ronnblom","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Vital","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Versnel","sequence":"additional","affiliation":[{"name":"Department of Immunology, Erasmus MC University Medical Center Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"2025090312514603000_9.1.e002864.1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3581"},{"key":"2025090312514603000_9.1.e002864.2","first-page":"1662","article-title":"Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy","volume":"56","author":"Psarras","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312514603000_9.1.e002864.3","doi-asserted-by":"crossref","DOI":"10.1186\/ar2886","article-title":"Type I interferon in organ-targeted autoimmune and inflammatory diseases","volume":"12 Suppl 1","author":"Crow","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.4","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32835c7e32"},{"key":"2025090312514603000_9.1.e002864.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206350"},{"key":"2025090312514603000_9.1.e002864.6","doi-asserted-by":"crossref","unstructured":"Burska AN , Rodr\u00edguez-Carrio J , Biesen R , et al . Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. RMD Open 2023.","DOI":"10.1136\/rmdopen-2022-002876"},{"key":"2025090312514603000_9.1.e002864.7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/0961203317716321","article-title":"Interferon alpha gene expression and serum level association with low vitamin D levels in Egyptian female patients with systemic lupus erythematosus","volume":"27","author":"Abdel Galil","year":"2018","journal-title":"Lupus"},{"key":"2025090312514603000_9.1.e002864.8","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312468964"},{"key":"2025090312514603000_9.1.e002864.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110983"},{"key":"2025090312514603000_9.1.e002864.10","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2019.05.012","article-title":"Bone marrow mesenchymal stem cells from patients with SLE maintain an interferon signature during in vitro culture","volume":"132","author":"Gao","year":"2020","journal-title":"Cytokine"},{"key":"2025090312514603000_9.1.e002864.11","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314546020"},{"key":"2025090312514603000_9.1.e002864.12","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1344-7","article-title":"IFN-\u03bb1 with th17 axis cytokines and IFN-\u03b1 define different subsets in systemic lupus erythematosus (SLE)","volume":"19","author":"Oke","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.6061\/clinics\/2012(02)11","article-title":"Clinical and serological manifestations associated with interferon-\u03b1 levels in childhood-onset systemic lupus erythematosus","volume":"67","author":"Postal","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"key":"2025090312514603000_9.1.e002864.14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejmhg.2011.06.009","article-title":"Serum interferon-alpha level in first degree relatives of systemic lupus erythematosus patients: correlation with autoantibodies titers","volume":"12","author":"Shahin","year":"2011","journal-title":"Egyptian Journal of Medical Human Genetics"},{"key":"2025090312514603000_9.1.e002864.15","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312437270"},{"key":"2025090312514603000_9.1.e002864.16","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1853-7","article-title":"Full high-throughput sequencing analysis of differences in expression profiles of long noncoding rnas and their mechanisms of action in systemic lupus erythematosus","volume":"21","author":"Ye","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5114\/ceji.2014.43728","article-title":"Serum level of eight cytokines in Han Chinese patients with systemic lupus erythematosus using multiplex fluorescent microsphere method","volume":"39","author":"Yin","year":"2014","journal-title":"Cent Eur J Immunol"},{"key":"2025090312514603000_9.1.e002864.18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1515\/jomb-2017-0048","article-title":"Potential immune biomarkers in diagnosis and clinical management for systemic lupus erythematosus","volume":"37","author":"Zecevic","year":"2018","journal-title":"J Med Biochem"},{"key":"2025090312514603000_9.1.e002864.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2005.07.009"},{"key":"2025090312514603000_9.1.e002864.20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.medcle.2019.07.003","article-title":"Increased interferon-1\u03b1, interleukin-10 and BLyS concentrations as clinical activity biomarkers in systemic lupus erythematosus","volume":"153","author":"Fern\u00e1ndez Matilla","year":"2019","journal-title":"Medicina Cl\u00ednica (English Edition)"},{"key":"2025090312514603000_9.1.e002864.21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-274605"},{"key":"2025090312514603000_9.1.e002864.22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jcla.20501","article-title":"MicroRNA146a expression in lupus patients with and without renal complications","volume":"26","author":"Hashad","year":"2012","journal-title":"J Clin Lab Anal"},{"key":"2025090312514603000_9.1.e002864.23","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313519157"},{"key":"2025090312514603000_9.1.e002864.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1636-6"},{"key":"2025090312514603000_9.1.e002864.25","doi-asserted-by":"crossref","DOI":"10.1186\/ar4479","article-title":"Vitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon alpha","volume":"16","author":"Mandal","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.26","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-017-1345-y","article-title":"Cytokine and autoantibody clusters interaction in systemic lupus erythematosus","volume":"15","author":"Pacheco","year":"2017","journal-title":"J Transl Med"},{"key":"2025090312514603000_9.1.e002864.27","first-page":"222","article-title":"Relationship between peripheral blood dendritic cells and cytokines involved in the pathogenesis of systemic lupus erythematosus","volume":"15","author":"Robak","year":"2004","journal-title":"Eur Cytokine Netw"},{"key":"2025090312514603000_9.1.e002864.28","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000026","article-title":"Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus","volume":"1","author":"Nielsen","year":"2014","journal-title":"Lupus Sci Med"},{"key":"2025090312514603000_9.1.e002864.29","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1649-1","article-title":"The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus","volume":"20","author":"Oliveira","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.30","article-title":"Clinical and immunologic profiles in incomplete lupus erythematosus and improvement with hydroxychloroquine treatment","volume":"2016","author":"Olsen","year":"2016","journal-title":"Autoimmune Dis"},{"key":"2025090312514603000_9.1.e002864.31","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1136\/annrheumdis-2018-213497","article-title":"Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome","volume":"77","author":"van den Hoogen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025090312514603000_9.1.e002864.32","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1501-z","article-title":"Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors?","volume":"20","author":"Wahadat","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.33","doi-asserted-by":"publisher","DOI":"10.1136\/mp.50.1.9"},{"key":"2025090312514603000_9.1.e002864.34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/cei.12957","article-title":"Interferon-\u0391 coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro","volume":"189","author":"Wirestam","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"2025090312514603000_9.1.e002864.35","doi-asserted-by":"publisher","DOI":"10.1191\/096120301678416042"},{"key":"2025090312514603000_9.1.e002864.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215571"},{"key":"2025090312514603000_9.1.e002864.37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161451"},{"key":"2025090312514603000_9.1.e002864.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1987.tb04111.x"},{"key":"2025090312514603000_9.1.e002864.39","first-page":"562","article-title":"Serum levels of interferons in patients with systemic lupus erythematosus","volume":"70","author":"Kim","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"2025090312514603000_9.1.e002864.40","doi-asserted-by":"crossref","DOI":"10.1186\/ar3017","article-title":"Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus","volume":"12","author":"Li","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.12.001"},{"key":"2025090312514603000_9.1.e002864.42","doi-asserted-by":"publisher","DOI":"10.1002\/art.23404"},{"key":"2025090312514603000_9.1.e002864.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.03.008"},{"key":"2025090312514603000_9.1.e002864.44","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000183","article-title":"Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases","volume":"2","author":"Flint","year":"2016","journal-title":"RMD Open"},{"key":"2025090312514603000_9.1.e002864.45","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000159","article-title":"Molecular signatures in systemic lupus erythematosus: distinction between disease flare and infection","volume":"3","author":"Mackay","year":"2016","journal-title":"Lupus Sci Med"},{"key":"2025090312514603000_9.1.e002864.46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clim.2016.08.018","article-title":"Novel molecular signatures in mononuclear cell populations from patients with systemic lupus erythematosus","volume":"172","author":"Olferiev","year":"2016","journal-title":"Clin Immunol"},{"key":"2025090312514603000_9.1.e002864.47","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.38628","article-title":"Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures","volume":"66","author":"Chiche","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025090312514603000_9.1.e002864.48","doi-asserted-by":"publisher","DOI":"10.1002\/art.27224"},{"key":"2025090312514603000_9.1.e002864.49","doi-asserted-by":"publisher","DOI":"10.2119\/2006-00085.Baechler"},{"key":"2025090312514603000_9.1.e002864.50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0337679100"},{"key":"2025090312514603000_9.1.e002864.51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067003","article-title":"SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature","volume":"8","author":"Becker","year":"2013","journal-title":"PLoS One"},{"key":"2025090312514603000_9.1.e002864.52","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygeno.2014.11.004","article-title":"Genome-wide transcriptional profiling of chronic cutaneous lupus erythematosus (CCLE) peripheral blood identifies systemic alterations relevant to the skin manifestation","volume":"105","author":"Dey-Rao","year":"2015","journal-title":"Genomics"},{"key":"2025090312514603000_9.1.e002864.53","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150326"},{"key":"2025090312514603000_9.1.e002864.54","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/art.39950","article-title":"Gene expression and pharmacodynamic changes in 1,760 systemic lupus erythematosus patients from two phase III trials of BAFF blockade with tabalumab","volume":"69","author":"Hoffman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312514603000_9.1.e002864.55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083776","article-title":"Cell-specific type I IFN signatures in autoimmunity and viral infection: what makes the difference?","volume":"8","author":"Kyogoku","year":"2013","journal-title":"PLoS ONE"},{"key":"2025090312514603000_9.1.e002864.56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044362","article-title":"Molecular characterization of circulating plasma cells in patients with active systemic lupus erythematosus","volume":"7","author":"Lugar","year":"2012","journal-title":"PLoS One"},{"key":"2025090312514603000_9.1.e002864.57","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg315"},{"key":"2025090312514603000_9.1.e002864.58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2011.01654.x"},{"key":"2025090312514603000_9.1.e002864.59","doi-asserted-by":"publisher","DOI":"10.1002\/art.37785"},{"key":"2025090312514603000_9.1.e002864.60","doi-asserted-by":"publisher","DOI":"10.1002\/art.24557"},{"key":"2025090312514603000_9.1.e002864.61","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204600"},{"key":"2025090312514603000_9.1.e002864.62","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-012-0907-y"},{"key":"2025090312514603000_9.1.e002864.63","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1050-x","article-title":"Whole-genome transcription and DNA methylation analysis of peripheral blood mononuclear cells identified aberrant gene regulation pathways in systemic lupus erythematosus","volume":"18","author":"Zhu","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.64","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000080","article-title":"Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE","volume":"2","author":"Kennedy","year":"2015","journal-title":"Lupus Sci Med"},{"key":"2025090312514603000_9.1.e002864.65","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2008.03646.x"},{"key":"2025090312514603000_9.1.e002864.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.08.014"},{"key":"2025090312514603000_9.1.e002864.67","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00393-017-0274-8","article-title":"Interferon-Stimulated gene 15 expression in systemic lupus erythematosus","volume":"77","author":"Yuan","year":"2018","journal-title":"Z Rheumatol"},{"key":"2025090312514603000_9.1.e002864.68","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/rheumatology\/kez116","article-title":"Increased expression of Fas on group 2 and 3 innate lymphoid cells is associated with an interferon signature in systemic lupus erythematosus and Sj\u00f6gren\u2019s syndrome","volume":"58","author":"Blokland","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312514603000_9.1.e002864.69","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10825.x"},{"key":"2025090312514603000_9.1.e002864.70","doi-asserted-by":"crossref","DOI":"10.1186\/ar4499","article-title":"T-Helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?","volume":"16","author":"Brkic","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.71","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1065-3","article-title":"The type I interferon signature in leukocyte subsets from peripheral blood of patients with early arthritis: a major contribution by granulocytes","volume":"18","author":"de Jong","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.72","doi-asserted-by":"crossref","DOI":"10.1186\/ar4448","article-title":"Elevated signal transducers and activators of transcription 1 correlates with increased C-C motif chemokine ligand 2 and C-X-C motif chemokine 10 levels in peripheral blood of patients with systemic lupus erythematosus","volume":"16","author":"Dominguez-Gutierrez","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.73","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-013-9973-3"},{"key":"2025090312514603000_9.1.e002864.74","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew288"},{"key":"2025090312514603000_9.1.e002864.75","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-24198-1","article-title":"A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features","volume":"8","author":"El-Sherbiny","year":"2018","journal-title":"Sci Rep"},{"key":"2025090312514603000_9.1.e002864.76","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316651738"},{"key":"2025090312514603000_9.1.e002864.77","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10067-014-2799-4","article-title":"Identification of interferon-inducible genes as diagnostic biomarker for systemic lupus erythematosus","volume":"34","author":"Feng","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2025090312514603000_9.1.e002864.78","doi-asserted-by":"crossref","DOI":"10.1186\/ar2510","article-title":"Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients","volume":"10","author":"Fu","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.79","doi-asserted-by":"publisher","DOI":"10.1172\/JCI124466"},{"key":"2025090312514603000_9.1.e002864.80","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000202","article-title":"Single-cell gene expression patterns in lupus monocytes independently indicate disease activity, interferon and therapy","volume":"4","author":"Jin","year":"2017","journal-title":"Lupus Sci Med"},{"key":"2025090312514603000_9.1.e002864.81","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.093146"},{"key":"2025090312514603000_9.1.e002864.82","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1007\/s10067-018-4138-7","article-title":"Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity","volume":"37","author":"Liu","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025090312514603000_9.1.e002864.83","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213386"},{"key":"2025090312514603000_9.1.e002864.84","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1929-4","article-title":"Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles","volume":"21","author":"Reynolds","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.85","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.03085","article-title":"Irf4 and irgs delineate clinically relevant gene expression signatures in systemic lupus erythematosus and rheumatoid arthritis","volume":"9","author":"Rodr\u00edguez-Carrio","year":"2018","journal-title":"Front Immunol"},{"key":"2025090312514603000_9.1.e002864.86","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308089694"},{"key":"2025090312514603000_9.1.e002864.87","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000508","article-title":"Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus","volume":"3","author":"Tyd\u00e9n","year":"2017","journal-title":"RMD Open"},{"key":"2025090312514603000_9.1.e002864.88","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-210485","article-title":"Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use","volume":"75","author":"van den Hoogen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025090312514603000_9.1.e002864.89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.02.001"},{"key":"2025090312514603000_9.1.e002864.90","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000286","article-title":"Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE","volume":"5","author":"Casey","year":"2018","journal-title":"Lupus Sci Med"},{"key":"2025090312514603000_9.1.e002864.91","doi-asserted-by":"crossref","DOI":"10.1186\/ar4451","article-title":"Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset","volume":"16","author":"Dominguez-Gutierrez","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.92","doi-asserted-by":"publisher","DOI":"10.1002\/art.22044"},{"key":"2025090312514603000_9.1.e002864.93","doi-asserted-by":"publisher","DOI":"10.1002\/art.21031"},{"key":"2025090312514603000_9.1.e002864.94","doi-asserted-by":"publisher","DOI":"10.1002\/art.23035"},{"key":"2025090312514603000_9.1.e002864.95","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.04057.x"},{"key":"2025090312514603000_9.1.e002864.96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2010.03.018"},{"key":"2025090312514603000_9.1.e002864.97","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1243-y","article-title":"Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis","volume":"19","author":"Wither","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.04.003"},{"key":"2025090312514603000_9.1.e002864.99","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaut.2018.09.007","article-title":"Epigenome-wide association study of peripheral blood mononuclear cells in systemic lupus erythematosus: identifying DNA methylation signatures associated with interferon-related genes based on ethnicity and SLEDAI","volume":"96","author":"Joseph","year":"2019","journal-title":"J Autoimmun"},{"key":"2025090312514603000_9.1.e002864.100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169553","article-title":"Genome-wide DNA methylation analysis of chinese patients with systemic lupus erythematosus identified hypomethylation in genes related to the type I interferon pathway","volume":"12","author":"Yeung","year":"2017","journal-title":"PLoS One"},{"key":"2025090312514603000_9.1.e002864.101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003678","article-title":"Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations","volume":"9","author":"Absher","year":"2013","journal-title":"PLoS Genet"},{"key":"2025090312514603000_9.1.e002864.102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.01.004"},{"key":"2025090312514603000_9.1.e002864.103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01686","article-title":"Shared and unique patterns of DNA methylation in systemic lupus erythematosus and primary sj\u00f6gren\u2019s syndrome","volume":"10","author":"Imgenberg-Kreuz","year":"2019","journal-title":"Front Immunol"},{"key":"2025090312514603000_9.1.e002864.104","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40422","article-title":"Twin DNA methylation profiling reveals flare-dependent interferon signature and B cell promoter hypermethylation in systemic lupus erythematosus","volume":"70","author":"Ulff-M\u00f8ller","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090312514603000_9.1.e002864.105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clim.2018.11.011","article-title":"Genome-wide DNA methylation analysis in primary antiphospholipid syndrome neutrophils","volume":"196","author":"Weeding","year":"2018","journal-title":"Clin Immunol"},{"key":"2025090312514603000_9.1.e002864.106","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208410"},{"key":"2025090312514603000_9.1.e002864.107","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/art.39029","article-title":"Interferon-\u0391 and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia","volume":"67","author":"Andrade","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090312514603000_9.1.e002864.108","doi-asserted-by":"publisher","DOI":"10.1002\/art.21890"},{"key":"2025090312514603000_9.1.e002864.109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037000","article-title":"Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients","volume":"7","author":"Somers","year":"2012","journal-title":"PLoS One"},{"key":"2025090312514603000_9.1.e002864.110","doi-asserted-by":"publisher","DOI":"10.1002\/art.23191"},{"key":"2025090312514603000_9.1.e002864.111","doi-asserted-by":"publisher","DOI":"10.1002\/art.34483"},{"key":"2025090312514603000_9.1.e002864.112","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364408"},{"key":"2025090312514603000_9.1.e002864.113","doi-asserted-by":"publisher","DOI":"10.1002\/art.20798"},{"key":"2025090312514603000_9.1.e002864.114","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2013.06.026","article-title":"Complement component c5a permits the co-existence of pathogenic th17 cells and type I interferon in lupus","volume":"63","author":"Biswas","year":"2013","journal-title":"Cytokine"},{"key":"2025090312514603000_9.1.e002864.115","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033753"},{"key":"2025090312514603000_9.1.e002864.116","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-212988"},{"key":"2025090312514603000_9.1.e002864.117","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/art.1780270523","article-title":"Periodicity of interferon appearance in serum of patients with systemic lupus erythematosus","volume":"27","author":"Lackovic","year":"1984","journal-title":"Arthritis Rheum"},{"key":"2025090312514603000_9.1.e002864.118","doi-asserted-by":"publisher","DOI":"10.1126\/science.6176024"},{"key":"2025090312514603000_9.1.e002864.119","doi-asserted-by":"publisher","DOI":"10.1002\/art.30313"},{"key":"2025090312514603000_9.1.e002864.120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197907053010102"},{"key":"2025090312514603000_9.1.e002864.121","first-page":"647","article-title":"Interferon in synovial fluid and serum of patients with rheumatic disease","volume":"10","author":"Cesario","year":"1983","journal-title":"J Rheumatol"},{"key":"2025090312514603000_9.1.e002864.122","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780250406"},{"key":"2025090312514603000_9.1.e002864.123","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780250407"},{"key":"2025090312514603000_9.1.e002864.124","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.trsl.2013.02.007","article-title":"The physiologic increase in expression of some type I IFN-inducible genes during pregnancy is not associated with improved disease activity in pregnant patients with rheumatoid arthritis","volume":"161","author":"Weix","year":"2013","journal-title":"Transl Res"},{"key":"2025090312514603000_9.1.e002864.125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086069","article-title":"IFN\u03b1 serum levels are associated with endothelial progenitor cells imbalance and disease features in rheumatoid arthritis patients","volume":"9","author":"Rodr\u00edguez-Carrio","year":"2014","journal-title":"PLoS One"},{"key":"2025090312514603000_9.1.e002864.126","first-page":"561","article-title":"Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis","volume":"12","author":"Lepore","year":"1994","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312514603000_9.1.e002864.127","doi-asserted-by":"publisher","DOI":"10.1002\/art.20998"},{"key":"2025090312514603000_9.1.e002864.128","first-page":"55","article-title":"Cytokine concentrations in the synovial fluid and plasma of rheumatoid arthritis patients: correlation with bony erosions","volume":"12","author":"Fong","year":"1994","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312514603000_9.1.e002864.129","first-page":"77","article-title":"A sensitive radioimmunoassay for alpha-interferon: circulating alpha-interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients","volume":"66","author":"Shiozawa","year":"1986","journal-title":"Clin Exp Immunol"},{"key":"2025090312514603000_9.1.e002864.130","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021553"},{"key":"2025090312514603000_9.1.e002864.131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024828","article-title":"Importance of correlation between gene expression levels: application to the type I interferon signature in rheumatoid arthritis","volume":"6","author":"Reynier","year":"2011","journal-title":"PLoS One"},{"key":"2025090312514603000_9.1.e002864.132","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.063412"},{"key":"2025090312514603000_9.1.e002864.133","doi-asserted-by":"crossref","DOI":"10.1186\/ar3271","article-title":"Risk factors for ANA positivity in healthy persons","volume":"13","author":"Li","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.134","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00285","article-title":"Type I interferon gene response is increased in early and established rheumatoid arthritis and correlates with autoantibody production","volume":"8","author":"Casta\u00f1eda-Delgado","year":"2017","journal-title":"Front Immunol"},{"key":"2025090312514603000_9.1.e002864.135","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-0946-9","article-title":"Physiological evidence for diversification of ifn\u03b1- and ifn\u03b2-mediated response programs in different autoimmune diseases","volume":"18","author":"de Jong","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.136","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.02007","article-title":"Heterogeneity of the type I interferon signature in rheumatoid arthritis: A potential limitation for its use as A clinical biomarker","volume":"8","author":"Rodr\u00edguez-Carrio","year":"2017","journal-title":"Front Immunol"},{"key":"2025090312514603000_9.1.e002864.137","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jaci.2017.08.026","article-title":"The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy","volume":"141","author":"Cooles","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2025090312514603000_9.1.e002864.138","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu299"},{"key":"2025090312514603000_9.1.e002864.139","doi-asserted-by":"publisher","DOI":"10.1002\/art.27226"},{"key":"2025090312514603000_9.1.e002864.140","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(88)90083-9"},{"key":"2025090312514603000_9.1.e002864.141","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.1780270517","article-title":"Acid labile alpha-interferon in sera and synovial fluids from patients with juvenile arthritis","volume":"27","author":"Arvin","year":"1984","journal-title":"Arthritis Rheum"},{"key":"2025090312514603000_9.1.e002864.142","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203447"},{"key":"2025090312514603000_9.1.e002864.143","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.tripleo.2008.09.015","article-title":"Association between IFN-alpha and primary Sjogren\u2019s syndrome","volume":"107","author":"Zheng","year":"2009","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"2025090312514603000_9.1.e002864.144","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12662","article-title":"Transcription profiling of peripheral B cells in antibody-positive primary Sj\u00f6gren\u2019s syndrome reveals upregulated expression of CX3CR1 and a type I and type II interferon signature","volume":"87","author":"Imgenberg-Kreuz","year":"2018","journal-title":"Scand J Immunol"},{"key":"2025090312514603000_9.1.e002864.145","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200738008"},{"key":"2025090312514603000_9.1.e002864.146","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1136\/annrheumdis-2015-eular.1811","article-title":"FRI0024 Interferon gamma-inducible protein 16 (IFI16) in rheumatoid arthritis: a novel biomarker for pulmonary involvement?","volume":"74","author":"Alunno","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025090312514603000_9.1.e002864.147","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202552"},{"key":"2025090312514603000_9.1.e002864.148","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000292","article-title":"SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sj\u00f6gren\u2019s syndrome","volume":"2","author":"Rose","year":"2016","journal-title":"RMD Open"},{"key":"2025090312514603000_9.1.e002864.149","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/29.1.50"},{"key":"2025090312514603000_9.1.e002864.150","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2009.20"},{"key":"2025090312514603000_9.1.e002864.151","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100486"},{"key":"2025090312514603000_9.1.e002864.152","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/rheumatology\/kez242","article-title":"Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sj\u00f6gren\u2019s syndrome in the JOQUER randomized trial","volume":"59","author":"Bodewes","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312514603000_9.1.e002864.153","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201381"},{"key":"2025090312514603000_9.1.e002864.154","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00281","article-title":"Single cell based phosphorylation profiling identifies alterations in toll-like receptor 7 and 9 signaling in patients with primary sj\u00f6gren\u2019s syndrome","volume":"10","author":"Davies","year":"2019","journal-title":"Front Immunol"},{"key":"2025090312514603000_9.1.e002864.155","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.07.002"},{"key":"2025090312514603000_9.1.e002864.156","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/art.38264","article-title":"Genome-Wide DNA methylation patterns in naive CD4+ T cells from patients with primary Sj\u00f6gren\u2019s syndrome","volume":"66","author":"Altorok","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025090312514603000_9.1.e002864.157","doi-asserted-by":"publisher","DOI":"10.1002\/art.23062"},{"key":"2025090312514603000_9.1.e002864.158","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.121400"},{"key":"2025090312514603000_9.1.e002864.159","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.188"},{"key":"2025090312514603000_9.1.e002864.160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00100","article-title":"The long non-coding RNA NRIR drives IFN-response in monocytes: implication for systemic sclerosis","volume":"10","author":"Mariotti","year":"2019","journal-title":"Front Immunol"},{"key":"2025090312514603000_9.1.e002864.161","doi-asserted-by":"publisher","DOI":"10.1002\/art.37742"},{"key":"2025090312514603000_9.1.e002864.162","doi-asserted-by":"publisher","DOI":"10.1002\/art.22382"},{"key":"2025090312514603000_9.1.e002864.163","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215770"},{"key":"2025090312514603000_9.1.e002864.164","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2008.98"},{"key":"2025090312514603000_9.1.e002864.165","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei244"},{"key":"2025090312514603000_9.1.e002864.166","doi-asserted-by":"publisher","DOI":"10.1002\/art.30318"},{"key":"2025090312514603000_9.1.e002864.167","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080418"},{"key":"2025090312514603000_9.1.e002864.168","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/275617","article-title":"Basal activation of type I interferons (alpha2 and beta) and 2\u2019 \u2019'OAS genes: insights into differential expression profiles of interferon system components in systemic sclerosis","volume":"2011","author":"de Oliveira","year":"2011","journal-title":"Int J Rheumatol"},{"key":"2025090312514603000_9.1.e002864.169","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207392"},{"key":"2025090312514603000_9.1.e002864.170","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.35"},{"key":"2025090312514603000_9.1.e002864.171","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.12.003"},{"key":"2025090312514603000_9.1.e002864.172","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/03009742.2012.736532","article-title":"Increased serum type I interferon activity in early systemic sclerosis patients is associated with antibodies against Sj\u00f6gren\u2019s syndrome antigens and nuclear ribonucleoprotein antigens","volume":"42","author":"Wuttge","year":"2013","journal-title":"Scand J Rheumatol"},{"key":"2025090312514603000_9.1.e002864.173","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11145.x"},{"key":"2025090312514603000_9.1.e002864.174","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139949"},{"key":"2025090312514603000_9.1.e002864.175","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.900843"},{"key":"2025090312514603000_9.1.e002864.176","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2011.61"},{"key":"2025090312514603000_9.1.e002864.177","doi-asserted-by":"publisher","DOI":"10.1002\/art.22928"},{"key":"2025090312514603000_9.1.e002864.178","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.05.011"},{"key":"2025090312514603000_9.1.e002864.179","doi-asserted-by":"publisher","DOI":"10.1002\/art.24936"},{"key":"2025090312514603000_9.1.e002864.180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01372","article-title":"CD19+CD24hiCD38hi B cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through toll-like receptor 7 and interferon-\u03b1","volume":"9","author":"Piper","year":"2018","journal-title":"Front Immunol"},{"key":"2025090312514603000_9.1.e002864.181","doi-asserted-by":"publisher","DOI":"10.1002\/art.24555"},{"key":"2025090312514603000_9.1.e002864.182","doi-asserted-by":"publisher","DOI":"10.1002\/art.38038"},{"key":"2025090312514603000_9.1.e002864.183","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12449"},{"key":"2025090312514603000_9.1.e002864.184","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209442"},{"key":"2025090312514603000_9.1.e002864.185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00487","article-title":"Type I interferon signature in primary antiphospholipid syndrome: clinical and laboratory associations","volume":"10","author":"Palli","year":"2019","journal-title":"Front Immunol"},{"key":"2025090312514603000_9.1.e002864.186","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.autrev.2018.11.004","article-title":"Enhanced type I interferon gene signature in primary antiphospholipid syndrome: association with earlier disease onset and preeclampsia","volume":"18","author":"Ugolini-Lopes","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2025090312514603000_9.1.e002864.187","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4246965","article-title":"Gene expression profiling in behcet\u2019s disease indicates an autoimmune component in the pathogenesis of the disease and opens new avenues for targeted therapy","volume":"2018","author":"Puccetti","year":"2018","journal-title":"J Immunol Res"},{"key":"2025090312514603000_9.1.e002864.188","first-page":"S34","article-title":"Dendritic cell subsets and type I interferon system in beh\u00e7et\u2019s disease: does functional abnormality in plasmacytoid dendritic cells contribute to th1 polarization?","volume":"25","author":"Pay","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312514603000_9.1.e002864.189","first-page":"84","article-title":"The expression of transmembrane and soluble CXCL16 and the relation with interferon-alpha secretion in patients with beh\u00e7et\u2019s disease","volume":"31","author":"Yilmaz","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312514603000_9.1.e002864.190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2249.2006.03253.x","article-title":"Interferon-Beta and adhesion molecules (E-selectin and s-intracellular adhesion molecule-1) are detected in sera from patients with retinal vasculitis and are induced in retinal vascular endothelial cells by Toll-like receptor 3 signalling","volume":"147","author":"Lee","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"2025090312514603000_9.1.e002864.191","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40620-016-0336-z","article-title":"Pathogenesis of antimicrobial peptides LL-37 and cpg-ODN in ANCA associated vasculitis","volume":"30","author":"Luan","year":"2017","journal-title":"J Nephrol"},{"key":"2025090312514603000_9.1.e002864.192","doi-asserted-by":"crossref","DOI":"10.1186\/ar4344","article-title":"The influence of cathelicidin LL37 in human anti-neutrophils cytoplasmic antibody (ANCA) -associated vasculitis","volume":"15","author":"Zhang","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.193","first-page":"1394","article-title":"Screening for key genes and transcription factors in ankylosing spondylitis by RNA-seq","volume":"15","author":"Xu","year":"2018","journal-title":"Exp Ther Med"},{"key":"2025090312514603000_9.1.e002864.194","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/cei.13376","article-title":"Serum IFI16 and anti-IFI16 antibodies in psoriatic arthritis","volume":"199","author":"De Andrea","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"2025090312514603000_9.1.e002864.195","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1080\/14397595.2018.1436029","article-title":"Stage classification of IgG4-related Dacryoadenitis and sialadenitis by the serum cytokine environment","volume":"28","author":"Yamamoto","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2025090312514603000_9.1.e002864.196","doi-asserted-by":"publisher","DOI":"10.1191\/096120300674499064"},{"key":"2025090312514603000_9.1.e002864.197","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu472sr"},{"key":"2025090312514603000_9.1.e002864.198","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201586"},{"key":"2025090312514603000_9.1.e002864.199","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex220"},{"key":"2025090312514603000_9.1.e002864.200","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315584811"},{"key":"2025090312514603000_9.1.e002864.201","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1878-y","article-title":"High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus","volume":"21","author":"Oke","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.202","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaut.2016.12.005","article-title":"Pathways of impending disease flare in african-american systemic lupus erythematosus patients","volume":"78","author":"Munroe","year":"2017","journal-title":"J Autoimmun"},{"key":"2025090312514603000_9.1.e002864.203","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030491","article-title":"Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus","volume":"3","author":"Bauer","year":"2006","journal-title":"PLoS Med"},{"key":"2025090312514603000_9.1.e002864.204","doi-asserted-by":"publisher","DOI":"10.1002\/art.24803"},{"key":"2025090312514603000_9.1.e002864.205","doi-asserted-by":"crossref","DOI":"10.1038\/srep29909","article-title":"Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in asian patients with systemic lupus erythematosus","volume":"6","author":"Connelly","year":"2016","journal-title":"Sci Rep"},{"key":"2025090312514603000_9.1.e002864.206","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1038\/s41598-018-20203-9","article-title":"Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus","volume":"8","author":"Connelly","year":"2018","journal-title":"Sci Rep"},{"key":"2025090312514603000_9.1.e002864.207","doi-asserted-by":"crossref","DOI":"10.1038\/srep27623","article-title":"Multiplex giant magnetoresistive biosensor microarrays identify interferon-associated autoantibodies in systemic lupus erythematosus","volume":"6","author":"Lee","year":"2016","journal-title":"Sci Rep"},{"key":"2025090312514603000_9.1.e002864.208","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311409963"},{"key":"2025090312514603000_9.1.e002864.209","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.074765"},{"key":"2025090312514603000_9.1.e002864.210","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaut.2015.04.002","article-title":"Widely divergent transcriptional patterns between SLE patients of different ancestral backgrounds in sorted immune cell populations","volume":"60","author":"Sharma","year":"2015","journal-title":"J Autoimmun"},{"key":"2025090312514603000_9.1.e002864.211","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.40086","article-title":"The biomarkers of lupus disease study: A bold approach may mitigate interference of background immunosuppressants in clinical trials","volume":"69","author":"Merrill","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312514603000_9.1.e002864.212","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/art.1780290407","article-title":"Induction of lupus inclusions by sera from patients with systemic lupus erythematosus","volume":"29","author":"Rich","year":"1986","journal-title":"Arthritis Rheum"},{"key":"2025090312514603000_9.1.e002864.213","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309105529"},{"key":"2025090312514603000_9.1.e002864.214","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep345"},{"key":"2025090312514603000_9.1.e002864.215","doi-asserted-by":"publisher","DOI":"10.1002\/art.27702"},{"key":"2025090312514603000_9.1.e002864.216","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/rheumatology\/kez335","article-title":"Unique Sj\u00f6gren\u2019s syndrome patient subsets defined by molecular features","volume":"59","author":"James","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312514603000_9.1.e002864.217","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00296-019-04335-3","article-title":"Associations of cigarette smoking with disease phenotype and type I interferon expression in primary Sj\u00f6gren\u2019s syndrome","volume":"39","author":"Olsson","year":"2019","journal-title":"Rheumatol Int"},{"key":"2025090312514603000_9.1.e002864.218","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.141051"},{"key":"2025090312514603000_9.1.e002864.219","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15006"},{"key":"2025090312514603000_9.1.e002864.220","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.40792","article-title":"Monitoring disease activity in systemic lupus erythematosus with single-molecule array digital enzyme-linked immunosorbent assay quantification of serum interferon-\u03b1","volume":"71","author":"Mathian","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312514603000_9.1.e002864.221","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150040"},{"key":"2025090312514603000_9.1.e002864.222","doi-asserted-by":"crossref","DOI":"10.1186\/ar2912","article-title":"Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment","volume":"12","author":"van Baarsen","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.223","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202753"},{"key":"2025090312514603000_9.1.e002864.224","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312514603000_9.1.e002864.225","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206090"},{"key":"2025090312514603000_9.1.e002864.226","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000284","article-title":"Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus","volume":"5","author":"Merrill","year":"2018","journal-title":"Lupus Sci Med"},{"key":"2025090312514603000_9.1.e002864.227","doi-asserted-by":"publisher","DOI":"10.1002\/art.37824"},{"key":"2025090312514603000_9.1.e002864.228","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.147199"},{"key":"2025090312514603000_9.1.e002864.229","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/art.38400","article-title":"Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray","volume":"66","author":"Sanayama","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025090312514603000_9.1.e002864.230","doi-asserted-by":"crossref","DOI":"10.1186\/ar3819","article-title":"The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients","volume":"14","author":"Raterman","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.231","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0564-y","article-title":"Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab","volume":"17","author":"de Jong","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025090312514603000_9.1.e002864.232","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208001"},{"key":"2025090312514603000_9.1.e002864.233","doi-asserted-by":"publisher","DOI":"10.1002\/art.34659"},{"key":"2025090312514603000_9.1.e002864.234","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-015-0710-3","article-title":"Biologic predictors of clinical improvement in rituximab-treated refractory myositis","volume":"16","author":"Reed","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"2025090312514603000_9.1.e002864.235","first-page":"719","article-title":"Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sj\u00f6gren\u2019s syndrome","volume":"35","author":"Quartuccio","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312514603000_9.1.e002864.236","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1002\/art.39108","article-title":"Randomized, double-blind, placebo-controlled trial of the effect of vitamin D3 on the interferon signature in patients with systemic lupus erythematosus","volume":"67","author":"Aranow","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090312514603000_9.1.e002864.237","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/art.40828","article-title":"Safety and tolerability of omalizumab: a randomized clinical trial of humanized anti-IgE monoclonal antibody in systemic lupus erythematosus","volume":"71","author":"Hasni","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312514603000_9.1.e002864.238","doi-asserted-by":"publisher","DOI":"10.1002\/art.34632"},{"key":"2025090312514603000_9.1.e002864.239","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.144485"},{"key":"2025090312514603000_9.1.e002864.240","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206016"},{"key":"2025090312514603000_9.1.e002864.241","doi-asserted-by":"crossref","DOI":"10.1186\/s12920-018-0468-1","article-title":"Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus","volume":"12","author":"Petri","year":"2019","journal-title":"BMC Med Genomics"},{"key":"2025090312514603000_9.1.e002864.242","doi-asserted-by":"publisher","DOI":"10.1007\/BF00269199"},{"key":"2025090312514603000_9.1.e002864.243","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.134254"},{"key":"2025090312514603000_9.1.e002864.244","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112545","article-title":"Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis","volume":"9","author":"Bienkowska","year":"2014","journal-title":"PLoS ONE"},{"key":"2025090312514603000_9.1.e002864.245","first-page":"655","article-title":"Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab","volume":"33","author":"L\u00f3pez De Padilla","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312514603000_9.1.e002864.246","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202794"},{"key":"2025090312514603000_9.1.e002864.247","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077974"},{"key":"2025090312514603000_9.1.e002864.248","doi-asserted-by":"publisher","DOI":"10.1038\/nri3787"},{"key":"2025090312514603000_9.1.e002864.249","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.10.004"},{"key":"2025090312514603000_9.1.e002864.250","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190459","article-title":"Type-I interferons in atherosclerosis","volume":"217","author":"Chen","year":"2020","journal-title":"J Exp Med"},{"key":"2025090312514603000_9.1.e002864.251","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1093\/rheumatology\/keac083","article-title":"Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicentre longitudinal study","volume":"61","author":"Wahadat","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312514603000_9.1.e002864.252","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964263","article-title":"Immunosuppressant exposure confounds gene expression analysis in systemic lupus erythematosus","volume":"13","author":"Northcott","year":"2022","journal-title":"Front Immunol"},{"key":"2025090312514603000_9.1.e002864.253","first-page":"482","article-title":"Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics","volume":"29","author":"Omdal","year":"2002","journal-title":"J Rheumatol"},{"key":"2025090312514603000_9.1.e002864.254","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00296-019-04354-0","article-title":"Fatigue in primary Sj\u00f6gren\u2019s syndrome (PSS) is associated with lower levels of proinflammatory cytokines: a validation study","volume":"39","author":"Davies","year":"2019","journal-title":"Rheumatol Int"},{"key":"2025090312514603000_9.1.e002864.255","first-page":"2318","article-title":"Fatigue in primary Sj\u00f6gren\u2019s syndrome is associated with an objective decline in physical performance, pain and depression","volume":"40","author":"Prak","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312514603000_9.1.e002864.256","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000282","article-title":"Fatigue in primary Sj\u00f6gren\u2019s syndrome is associated with lower levels of proinflammatory cytokines","volume":"2","author":"Howard Tripp","year":"2016","journal-title":"RMD Open"},{"key":"2025090312514603000_9.1.e002864.257","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.41489","article-title":"Improvement of severe fatigue following nuclease therapy in patients with primary Sj\u00f6gren\u2019s syndrome: a randomized clinical trial","volume":"73","author":"Posada","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090312514603000_9.1.e002864.258","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00296-021-04927-y","article-title":"Revisiting the JOQUER trial: stratification of primary Sj\u00f6gren\u2019s syndrome and the clinical and interferon response to hydroxychloroquine","volume":"41","author":"Collins","year":"2021","journal-title":"Rheumatol Int"},{"key":"2025090312514603000_9.1.e002864.259","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/rheumatology\/kex490","article-title":"Systemic interferon type I and type II signatures in primary Sj\u00f6gren\u2019s syndrome reveal differences in biological disease activity","volume":"57","author":"Bodewes","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312514603000_9.1.e002864.260","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.2727"},{"key":"2025090312514603000_9.1.e002864.261","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.1278"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:52:08Z","timestamp":1756929128000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":261,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3,7]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/rmdopen-2022-002864"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002864","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}